– http://www.reuters.com/healthNews
ZURICH (Reuters) – Swiss drugmaker Roche said on Monday the European Commission had approved a new formulation of its breast cancer drug Herceptin which allows the medicine to be administered more quickly.
Continue Reading On http://www.reuters.com/healthNews »
AMSTERDAM, Sept 2 (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed.
Continue Reading On http://www.reuters.com »
– http://www.reuters.com/healthNews
COPENHAGEN (Reuters) – Danish pharmaceutical group Lundbeck has filed an appeal against a 93.8 million euros ($123.7 million) fine by the European Commission for deals with rivals to block the supply of generic versions of its citalopra anti-depressant to the market.
Continue Reading On http://www.reuters.com/healthNews »
BRUSSELS, Sept 2 (Reuters) – Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE.
Continue Reading On http://www.reuters.com »
– http://www.reuters.com/healthNews
NEW YORK (Reuters Health) – Helping people who were recently released from a hospital understand how to care for themselves and informing their primary care doctors about their stay may reduce their risk of being admitted back into the hospital, says a new study.
Continue Reading On http://www.reuters.com/healthNews »
– http://www.reuters.com/healthNews
AMSTERDAM (Reuters) – An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed.
Continue Reading On http://www.reuters.com/healthNews »
No down payment medical, dental and healthcare provider practice financing here! + More News: Lundbeck appeals against EU Commission fine + MORE 09/02/2013
No comments:
Post a Comment